Loading ...
All potential drugscan causeadverse events
unapproved drugs(passive) caused byadverse events
generic drugs(passive) triggered byadverse events
ADHD drugs(passive) caused byadverse events
study drugs(passive) caused byadverse events
this group of drugs(passive) caused byadverse events
other psychotropic drugs(passive) caused byadverse events
some of its cancer drugs(passive) caused byadverse events
to use FDA - approved drugsto preventadverse events
drug interactions and drugs that prolong the QT interval , especially those affecting women(passive) caused byadverse events
Any drug ( including over - the - counter drugscan causeadverse events
antihypertensive drugs helpto preventadverse events
FDA - regulated drugs(passive) caused byadverse events
potentially inappropriate medications ( PIMs ) and drug - drug interactions ( DDIs(passive) caused byadverse events
using the pharmaceutical product(passive) caused byadverse events
the drugs which are more likely to work for that patient and less likelyto causeadverse events
atypical antipsychotic drugs(passive) caused byadverse events
animal feed or drugs(passive) caused byadverse events
drugs once they 're approved(passive) caused byadverse events
newly approved drugs(passive) caused byadverse events
a combination of prescription drugsmay causeadverse events
a drug or device(passive) might be caused byAdverse events
all drugs and treatments for human diseases(passive) caused byadverse events
drug use(passive) caused byadverse events
Wen ProductsWere CausingAdverse Events
pharmaceutical products(passive) caused byadverse events
sanitizing products(passive) caused byadverse events
these recalled products(passive) caused byadverse events
the concurrent taking of drugs and natural health products(passive) created byAdverse events
a Drug Warning(passive) Caused byAdverse Events
drug withdrawal(passive) might be triggered byAdverse events
the drug or intervention(passive) caused byadverse events
the drug.9(passive) caused byadverse events
drug overexposure(passive) can be caused byAdverse Events
the study drug(passive) caused byadverse events
drug sharing(passive) caused byadverse events
potential drug - drug interactions in an intensive care unit of a teaching hospital(passive) caused byAdverse events
chemotherapy treatment 50(passive) are ... caused byadverse events
the less effective drugs and biologics(passive) caused byadverse events
misuse , abuse , and drug interactions(passive) caused byadverse events
to permanent discontinuation of study drug or withdrawal from studyleadingto permanent discontinuation of study drug or withdrawal from study
to treatment discontinuation or interruptionleadingto treatment discontinuation or interruption
to premature treatment discontinuationleadingto premature treatment discontinuation
to atezolizumab treatment discontinuationledto atezolizumab treatment discontinuation
to Permanent Discontinuation From Any Study Drug Incidence of Adverse EventsLeadingto Permanent Discontinuation From Any Study Drug Incidence of Adverse Events
to treatment discontinuation ( 26 % vs. 3 %ledto treatment discontinuation ( 26 % vs. 3 %
to treatment discontinuation in 24 % of patientsledto treatment discontinuation in 24 % of patients
in dose reduction or treatment discontinuationresultin dose reduction or treatment discontinuation
to premature discontinuation of study drug Experimentalleadingto premature discontinuation of study drug Experimental
to treatment discontinuation [ Time Frame : 52 weeksleadingto treatment discontinuation [ Time Frame : 52 weeks
to treatment discontinuation [ Time Frame : 36 monthsleadingto treatment discontinuation [ Time Frame : 36 months
to treatment discontinuation in 5.9 %ledto treatment discontinuation in 5.9 %
to permanent discontinuation of treatment with defibrotide sodiumleadingto permanent discontinuation of treatment with defibrotide sodium
to drug discontinuation of treatmentledto drug discontinuation of treatment
during treatment and resulted in discontinuation of the study drugcreatedduring treatment and resulted in discontinuation of the study drug
adverse events and treatment discontinuation(passive) caused byadverse events and treatment discontinuation
to treatment discontinuation ( 45 eventsleadingto treatment discontinuation ( 45 events
to T - DM1 or combination treatment discontinuationleadingto T - DM1 or combination treatment discontinuation
to treatment discontinuation in 12 % of the prescriptionsledto treatment discontinuation in 12 % of the prescriptions
to treatment discontinuation in 13 % of patientsledto treatment discontinuation in 13 % of patients
to treatment discontinuation by baseline BPleadingto treatment discontinuation by baseline BP
to Discontinuation of Study Drug From Baseline to EOTLeadingto Discontinuation of Study Drug From Baseline to EOT
to study treatment discontinuation , modification , or interruptionleadingto study treatment discontinuation , modification , or interruption
to death or to discontinuation from treatmentleadingto death or to discontinuation from treatment
to treatment discontinuation in 20 % vs 2 %leadingto treatment discontinuation in 20 % vs 2 %
to treatment discontinuation in 9 patients ( 8 %ledto treatment discontinuation in 9 patients ( 8 %
to treatment discontinuation or death noted in the studyleadingto treatment discontinuation or death noted in the study
to premature discontinuation of study drug [ Time Frameleadingto premature discontinuation of study drug [ Time Frame
to discontinuation of study drug from the start of study treatment untilledto discontinuation of study drug from the start of study treatment until
to premature discontinuation of treatmentleadingto premature discontinuation of treatment
to premature study drug discontinuationledto premature study drug discontinuation
to treatment discontinuation during the open - label phaseleadingto treatment discontinuation during the open - label phase
to treatment discontinuation in 61 other patients ( 19ledto treatment discontinuation in 61 other patients ( 19
to study treatment discontinuation / Modification [ Time Frameleadingto study treatment discontinuation / Modification [ Time Frame
to treatment discontinuation with Zyban R included tremorsleadingto treatment discontinuation with Zyban R included tremors
to Permanent Discontinuation of the Study Medication [ Time FrameLeadingto Permanent Discontinuation of the Study Medication [ Time Frame
to treatment discontinuation in 9 patients ( 20.9 %ledto treatment discontinuation in 9 patients ( 20.9 %
in premature discontinuation of study drug in Desonate treated subjectsresultedin premature discontinuation of study drug in Desonate treated subjects
to treatment discontinuation , other adverse events , and quality of lifeleadingto treatment discontinuation , other adverse events , and quality of life
to discontinuation of study drug by treatment group ( Safety setleadingto discontinuation of study drug by treatment group ( Safety set